ACCESSWIRE
22 Mar 2023, 16:43 GMT+10
GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, March 22, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced an invitation to its industry symposium at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders on Friday, March 31, 2023. This is an official symposium of the International Conference on Alzheimer's and Parkinson's Diseases 2023, AD/PD™ 2023.
The IRLAB-sponsored symposium with the title The management dilemma of Parkinson's disease progression and emerging treatment approaches has a distinguished panel of leading experts that will address the challenges in managing Parkinson's. This innovative program will be chaired by Mike Ward, medical journalist, with speakers addressing the patient journey and clinical management priorities (Professor Karl Kieburtz, USA); how biomarkers may redefine our notion about Parkinson's (Dr Ken Marek, USA); the emerging treatments across the progression of the Parkinson's (Professor Joakim Tedroff, Sweden). Panel discussions will be held with opportunities to answer questions from the audience and for speakers to share key learnings from their fields. The symposium will take place on Friday, March 31 from 13:50 - 15:50 in Hall F1+F2+F3.
The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders 2023, AD/PD™ 2023, will take place on March 28 - April 1, 2023, at Svenska Mässan Gothia Towers in Gothenburg, Sweden. More information about the congress can be found on www.adpd.kenes.com.
This session is not included in the main event CME/CPD credit.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
Attachments
SOURCE: IRLAB Therapeutics
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationWASHINGTON D.C.: In response to a safety warning issued by the US National Highway Traffic Safety Administration, Vietnamese electric vehicle ...
NEW YORK CITY, New York: Electric truck manufacturer Nikola Corp said that Nasdaq has delivered a delisting notice for not ...
MINNEAPOLIS, Minnesota: Reuters reported that after facing a backlash from customers, Target is pulling some products from its Pride Collection ...
LONDON, England: The BBC has reported that Jaguar Land Rover owner Tata Motors is planning to build a multi-billion pound ...
MENLO Park, California: As part of the last stage of a three-series round of staff layoffs, part of a plan ...
WASHINGTON D.C.: On its website, the US Federal Trade Commission (FTC) has said it is probing Abbott Laboratories and other ...
CHICAGO, Illinois: Boosted by an ongoing shortage of previously owned houses on the market and a considerable drop in prices ...
Two veteran pitchers very familiar with the opponent are scheduled to go head-to-head Monday when the Pittsburgh Pirates visit the ...
After spinning their wheels during a 3-4 road trip through Ohio, the St. Louis Cardinals will try to regain traction ...
Averaging just 2.9 runs per game in May, the Cleveland Guardians will attempt to kickstart their offense when they open ...
Isaac Paredes homered and drove in four runs, and Wander Franco chipped in with two hits and two RBIs to ...
Goals off corner kicks by Fafa Picault and Teal Bunbury rallied host Nashville SC to a 3-1 victory against the ...